CARDINAL HEALTH INC

Cardinal Health’s Q4 earnings reveal a resilient pharma player: strong ROIC, conservative leverage, and a steady $0.52 dividend, amid rising rates and supply‑chain challenges.

Cardinal Health’s FY 2025 10‑K shows disciplined growth, strong specialty‑solutions expansion, and robust governance—insights that help investors gauge future value.

Cardinal Health’s recent insider filings reveal routine equity‑based sales, steady governance, and a focus on digital expansion amid pricing and regulatory pressures.

Cardinal Health’s Q4 2026 results show a 4.3% revenue lift and 12.7% net income rise, driven by specialty pharma and home‑care expansion, positioning it for value‑based care contracts.

Cardinal Health (CAH) gears up for next week’s earnings, offering insight into pharma logistics, supply‑chain resilience and inflation‑driven margins.

Cardinal Health’s senior execs buy shares at zero price in August 2026, boosting confidence and showing alignment of management with shareholders amid growing healthcare‑logistics consolidation.

Cardinal Health’s $360 M acquisition of AdaptHealth’s diabetes unit and Strive Medical’s portfolio boosts its home‑care footprint, targeting $22 M EBITDA in 12 months.

Cardinal Health’s Solaris Health acquisition and Cardiovascular Logistics’ new CEO illustrate the trend toward physician‑centered, data‑driven specialty networks that boost care coordination, cut readmissions, and align with value‑based CMS programs.

Cardinal Health’s atumelnant shows early promise for CAH and Cushing’s, offering an oral ACTH‑antagonist that reduces cortisol and androgen levels safely.

Cardinal Health’s Rule 144 filing shows insider sales, market effects, and future risks—offering investors insight into liquidity, regulatory shifts, and potential upside.